The Consumer Healthcare Products Association (CHPA) today announced the election of Michelle Wang Goodridge as the new Chair of the CHPA Board of Directors. Goodridge was elected along with six new board members.
In keeping with the mission of the FDA Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology Division of Medication Error and Prevention Analysis, this CHPA member feedback is designed to minimize the risk of medication errors due to consumer confusion attributed to an OTC drug product name.
PCPC and CHPA appreciate the opportunity to comment on FDA Notice of Intent to Prepare and Environmental Impact Statement to evaluate environmental effects for marketing certain OTC sunscreen products.
Consumer self-care changed during the COVID-19 pandemic. This report from IRI and CHPA divides consumers into seven distinct segments and discussed how CPGs and retailers can reach them with the right health and wellness solutions.
What does climate change and environmental policy have to do with FDA approved self-care products? More than you’d think! Hear from Carlos Gutierrez and Kevin Canan as they dig into what’s ahead for the consumer healthcare industry when it comes to environmental rules and regulations.
CHPA is writing to request that FDA exercise its enforcement discretion and not take enforcement action against companies choosing to include a warning related to pregnancy on monograph product labels.
COVID-19 has taught us a lot about minimizing our risk and focusing on wellness and prevention in our lives. Anita and John dig into what this shift means to the dietary supplements category of the consumer healthcare industry.
CHPA launched a new podcast – CHPA Chat – providing stories and insights from staff, industry leaders, academics, and healthcare providers about the trends and issues facing the consumer healthcare space.
